Yasheng's Provisionally Patented Technology Aims to Use AI in Immunotherapy Development

Yasheng Group, an agricultural and biotech company with U.S. headquarters in San Jose, California today announced that HERB filed for patent protection with the USPTO. The invention relates to the use of artificial intelligence (AI) to improve cancer immunotherapy.

The provisionally patented technology aims to use AI in various aspects of immunotherapy development, including antigen characterizations, AI-based immune signatures, prediction of immunotherapy responses, manufacturing optimization, and AI assistance in clinical trials.

AI can assist in identifying antigens and binding sites for CAR T-cell therapies, characterizing the tumor-immune microenvironment, and predicting immunotherapy responses. It can also optimize the manufacturing process of CAR-T and CAR-NK cell therapies, reducing time and costs and improving clinical success rates.

The invention's unique features include the use of AI in multiple aspects of immunotherapy development, which has the potential to improve diagnostic accuracy, optimize treatment planning, predict outcomes of care, and reduce human resource costs.

Source: https://yashenggroup.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type